Neil H Segal

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi request reprint Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
  2. pmc Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
  3. ncbi request reprint Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital, Division of Surgical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Res 135:282-90. 2006
  4. ncbi request reprint Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
  5. ncbi request reprint Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
  6. ncbi request reprint EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, and Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 12:5356-62. 2006
  7. ncbi request reprint Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A
    Kara Y Detwiller
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 65:5881-9. 2005
  8. doi request reprint Nivolumab plus ipilimumab in advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 369:122-33. 2013
  9. ncbi request reprint Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
  10. pmc CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008

Detail Information

Publications11

  1. ncbi request reprint Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  2. pmc Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
    ..In conclusion, we showed gene expression profiling to be useful in classification and diagnosis, providing insights into pathogenesis and pointing to potential new therapeutic targets of soft tissue sarcoma...
  3. ncbi request reprint Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital, Division of Surgical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Res 135:282-90. 2006
    ..The aim of this study was to develop profiles of angiogenesis-related gene and protein expression for various histologic subtypes of soft tissue sarcomas (STS) growing in different sites...
  4. ncbi request reprint Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
    ..Further studies of these selected novel STS antigens are warranted to identify and characterize potential antigen targets expressed by STS...
  5. ncbi request reprint Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
    ....
  6. ncbi request reprint EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, and Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 12:5356-62. 2006
    ..CCS arising in the gastrointestinal tract is rare and its pathologic and molecular features are not well defined...
  7. ncbi request reprint Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A
    Kara Y Detwiller
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 65:5881-9. 2005
    ..We conclude that hypoxia plays an important role in human sarcomas but hypoxic up-regulation of VEGF-A expression does not attenuate the efficacy of VEGF-A RNA interference...
  8. doi request reprint Nivolumab plus ipilimumab in advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 369:122-33. 2013
    ..On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma...
  9. ncbi request reprint Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  10. pmc CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
    ..These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade...
  11. doi request reprint Epitope landscape in breast and colorectal cancer
    Neil H Segal
    Department of Medicine, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:889-92. 2008
    ..These data suggest that, with appropriate manipulation of the immune system, tumor cell destruction in situ may provide a polyvalent tumor vaccine without a requirement for knowledge of the targeted antigens...